BVF Inc IL Portfolio Activity in Q2 2026

Based on the provided portfolio data for BVF Inc IL, significant changes occurred in its holdings during Q2 2026. The investor's total portfolio value stood at $3.18 billion as of June 30, 2026.

Several notable purchases were observed this quarter:

• XOMA: BVF Inc IL significantly increased its stake in XOMA ROYALTY CORPORATION (XOMA) by acquiring an additional 5,003,000 shares (193.14% increase), boosting its portfolio allocation to 8.25%. This substantial addition suggests strong confidence in this holding.
• QTTB: The investor made a fresh purchase of Q32 BIO INC (QTTB) shares, acquiring 2,350,000 new shares, resulting in a 100% increase and adding this stock to the portfolio with an allocation of 0.77%.
• ABSI: Similarly, ABSCI CORPORATION (ABSI) saw its entire position replaced by BVF Inc IL through a fresh purchase of 2,361,674 shares, representing a 100% increase from the previous period.
• SGMT: Sagimet Biosciences (SGMT) was also added or significantly bolstered by BVF Inc IL with a fresh purchase of 2,500,000 shares, marking a 100% increase and contributing 0.49% to the portfolio.

Conversely, BVF Inc IL also divested from certain stocks during Q2:

• KYMER (KYMR): The investor sold a substantial portion of their holdings in KYMERA THERAPEUTICS INC (KYMR), reducing the position by 1,630,658 shares (-29.63% change). This exit decreased its portfolio allocation from 14.2% to 11.35%, indicating a strategic withdrawal.
• MIRM (MIRUM): Mirum Pharmaceuticals experienced an even larger reduction, with BVF Inc IL selling 528,700 shares (-33.36% change), lowering its allocation from 14.2% to 3.16%. This significant sell-off suggests a major shift away from this stock.
• TYRA (TYRA): Tyra Biosciences saw an exit of 500,000 shares (-25.3% change), further reducing its portfolio allocation.

In addition to these major shifts, BVF Inc IL made several smaller adjustments:

• MLTX (MOONLAKE): The position in Moonlake Immunotherapeutics remained unchanged (0% change). This stability is noted despite the overall portfolio changes.
• GPCR (STRUCTURE): Structure Therapeutics saw a slight reduction in shares (-2.67%), though not as drastic as other exits, and its allocation decreased slightly from 4.62% to an unspecified level.
• RVMD (REVOLUTION): Revolution Medicines experienced a small increase (+3.79%) but remained within the same sector allocations overall.

The investor also added new positions during this quarter:

• IVVD (INVIVYD): A fresh purchase of 28,165,000 shares in Invivyd Inc was recorded.
• G01767105 (ALKERMES): Alkermes PLC saw a fresh purchase of 2,154,704 shares (+7.74% change), adding this position.
• ZYME (ZYMEWORKS): ZymeWorks Inc was added with a fresh purchase of 3,649,142 shares.

Furthermore, BVF Inc IL made minor adjustments to other holdings:

• XNCR (XENCOR): The position in Xencor remained static (0% change
• GLUE (MONTE ROSA): Monte Rosa Therapeutics saw no change (-0.0%, 0 shares added).
• C_gem (CULLINAN): Cullinan Therapeutics experienced a slight increase in allocation (+0.68%) due to unchanged or slightly increased holdings.

Overall, BVF Inc IL's portfolio saw significant turnover during Q2 2026, marked by substantial purchases (particularly XOMA) and notable exits from positions like KYMR and MIRM.